Donald Hooker
Stock Analyst at Keybanc
(2.84)
# 1,711
Out of 4,784 analysts
82
Total ratings
55.95%
Success rate
17.03%
Average return
Main Sectors:
Stocks Rated by Donald Hooker
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TDOC Teladoc Health | Maintains: Overweight | $180 → $100 | $8.09 | +1,136.09% | 18 | Feb 23, 2022 | |
| CRL Charles River Laboratories International | Maintains: Overweight | $450 → $390 | $155.55 | +150.72% | 5 | Feb 17, 2022 | |
| DGX Quest Diagnostics | Maintains: Overweight | $168 → $170 | $167.33 | +1.60% | 4 | Dec 13, 2021 | |
| IQV IQVIA Holdings | Maintains: Overweight | $270 → $290 | $177.39 | +63.48% | 4 | Nov 17, 2021 | |
| PHR Phreesia | Maintains: Overweight | $70 → $73 | $26.00 | +180.77% | 8 | Jul 12, 2021 | |
| RXRX Recursion Pharmaceuticals | Initiates: Overweight | $36 | $5.81 | +519.62% | 1 | May 11, 2021 | |
| AMWL American Well | Initiates: Sector Weight | n/a | $7.82 | - | 1 | Apr 16, 2021 | |
| VEEV Veeva Systems | Maintains: Overweight | $332 → $353 | $234.21 | +50.72% | 2 | Feb 17, 2021 | |
| HQY HealthEquity | Downgrades: Sector Weight | n/a | $86.96 | - | 11 | Dec 2, 2020 | |
| MMS Maximus | Maintains: Overweight | $80 → $84 | $68.21 | +23.15% | 2 | Aug 7, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Weight | n/a | $9.60 | - | 8 | Jul 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $212 → $170 | $230.02 | -26.09% | 7 | Mar 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Weight | n/a | $179.07 | - | 6 | Sep 23, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $68 → $46 | $1.41 | +3,162.41% | 2 | Nov 13, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Weight | n/a | $19.14 | - | 1 | Oct 24, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Weight | n/a | $312.36 | - | 2 | Jul 10, 2017 |
Teladoc Health
Feb 23, 2022
Maintains: Overweight
Price Target: $180 → $100
Current: $8.09
Upside: +1,136.09%
Charles River Laboratories International
Feb 17, 2022
Maintains: Overweight
Price Target: $450 → $390
Current: $155.55
Upside: +150.72%
Quest Diagnostics
Dec 13, 2021
Maintains: Overweight
Price Target: $168 → $170
Current: $167.33
Upside: +1.60%
IQVIA Holdings
Nov 17, 2021
Maintains: Overweight
Price Target: $270 → $290
Current: $177.39
Upside: +63.48%
Phreesia
Jul 12, 2021
Maintains: Overweight
Price Target: $70 → $73
Current: $26.00
Upside: +180.77%
Recursion Pharmaceuticals
May 11, 2021
Initiates: Overweight
Price Target: $36
Current: $5.81
Upside: +519.62%
American Well
Apr 16, 2021
Initiates: Sector Weight
Price Target: n/a
Current: $7.82
Upside: -
Veeva Systems
Feb 17, 2021
Maintains: Overweight
Price Target: $332 → $353
Current: $234.21
Upside: +50.72%
HealthEquity
Dec 2, 2020
Downgrades: Sector Weight
Price Target: n/a
Current: $86.96
Upside: -
Maximus
Aug 7, 2020
Maintains: Overweight
Price Target: $80 → $84
Current: $68.21
Upside: +23.15%
Jul 6, 2020
Downgrades: Sector Weight
Price Target: n/a
Current: $9.60
Upside: -
Mar 30, 2020
Maintains: Overweight
Price Target: $212 → $170
Current: $230.02
Upside: -26.09%
Sep 23, 2019
Downgrades: Sector Weight
Price Target: n/a
Current: $179.07
Upside: -
Nov 13, 2017
Maintains: Overweight
Price Target: $68 → $46
Current: $1.41
Upside: +3,162.41%
Oct 24, 2017
Downgrades: Sector Weight
Price Target: n/a
Current: $19.14
Upside: -
Jul 10, 2017
Downgrades: Sector Weight
Price Target: n/a
Current: $312.36
Upside: -